Anne Bernadette Chang

1 month ago | cell.com | Ilse Dewachter |Gunter Hoglinger |Daniel J. Drucker |Roland Martin |Anne Bernadette Chang |Sanjay Haresh Chotirmall | +2 more

Main textAD remains a major societal challenge, but more than a century of research is gradually leading to an exciting (r)evolution in AD and other tauopathy trials. Initially, amyloid-beta-targeting trials faced significant failures, but recent successes with lecanemab (Clarity AD) and donanemab (TRAILBLAZER-ALZ 2) demonstrated substantial amyloid clearance and significant clinical benefits.